-
公开(公告)号：US12049489B2
公开(公告)日：2024-07-30
申请号：US18340707
申请日：2023-06-23
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Andrew Tustian , Ankit Vartak , Thomas Daly , Erica Pyles , Nisha Palackal , Shunhai Wang , Ning Li
IPC: C07K1/36 , A61K38/18 , C07K1/113 , C07K1/16 , C07K1/18 , C07K1/22 , C07K14/71 , C07K16/22 , C07K16/28 , C12N5/00 , C12N15/66 , C12P21/02 , C12P21/06 , G01N30/80 , G01N30/02
CPC classification number: C07K14/71 , A61K38/1866 , C07K1/113 , C07K1/16 , C07K1/18 , C07K1/22 , C07K1/36 , C07K16/22 , C07K16/283 , C12N5/0018 , C12N5/0031 , C12N15/66 , C12P21/02 , C12P21/06 , G01N30/80 , C07K2317/622 , C07K2319/30 , C07K2319/33 , C12N2800/10 , G01N2030/027
Abstract: The present disclosure pertains to methods for producing aflibercept from a host cell cultured in a chemically defined medium (CDM) including purification of aflibercept, wherein aflibercept following purification includes aflibercept variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine and a combination thereof.
-
公开(公告)号：US20230348532A1
公开(公告)日：2023-11-02
申请号：US18175914
申请日：2023-02-28
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： John Mattila , Xiaolin Tang , Hanne Bak , Shawn M. Lawrence , Amy S. Johnson , Meghan Casey , Michelle LaFond , Andrew Tustian , Philip Mellors , John Hourihan , John Crowley , Laura Callinan , Shadia Abike Oshodi , Ashley Witmer , Daniel Corbett , James Reilly , Ankit Vartak , Mark Chiboroski , Alessandra Starling , Robert Stairs , Hai-Yuan Goh , Liam Nicholl , Aishling Conlon
CPC classification number: C07K1/36 , C07K16/244 , C07K2317/565
Abstract: The present invention pertains to methods for manufacturing high titer antibody products. In particular, the invention pertains, in part, to improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Additionally, the present invention further pertains to chromatographic procedures employed to successfully isolate the antibody product subject of the present disclosure.
-
公开(公告)号：US11459373B2
公开(公告)日：2022-10-04
申请号：US17500735
申请日：2021-10-13
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Andrew Tustian , Ankit Vartak , Thomas Daly , Erica Pyles , Nisha Palackal , Shunhai Wang , Ning Li
IPC: C07K1/36 , C07K14/71 , C12P21/06 , C07K1/113 , C07K1/16 , C12N5/00 , C07K1/18 , C07K1/22 , C12P21/02 , A61K38/18 , C07K16/28 , C12N15/66 , C07K16/22 , G01N30/80 , G01N30/02
Abstract: The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using anion exchange chromatography to produce aflibercept with a specific glycosylation profile. In particular, these methods produce aflibercept with a glycosylation profile with specific ranges of % total fucosylated glycans, total sialylated glycans, mannose-5, and galactosylated glycans.
-
公开(公告)号：US20220235116A1
公开(公告)日：2022-07-28
申请号：US17711723
申请日：2022-04-01
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Andrew Tustian , Ankit Vartak , Thomas Daly , Erica Pyles , Nisha Palackal , Shunhai Wang , Ning Li , Matthew Franklin
IPC: C07K14/71 , C12P21/06 , C07K1/113 , C07K1/16 , C07K1/36 , C12N5/00 , C07K1/18 , C07K1/22 , C12P21/02 , A61K38/18 , C07K16/28 , C12N15/66 , C07K16/22 , G01N30/80
Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
-
公开(公告)号：US20210214430A1
公开(公告)日：2021-07-15
申请号：US16996042
申请日：2020-08-18
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Andrew Tustian , Ankit Vartak , Thomas Daly , Erica Pyles , Nisha Palackal
Abstract: The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce amounts of certain aflibercept variants.
-
公开(公告)号：US20240067701A1
公开(公告)日：2024-02-29
申请号：US18340707
申请日：2023-06-23
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Andrew Tustian , Ankit Vartak , Thomas Daly , Erica Pyles , Nisha Palackal , Shunhai Wang , Ning Li
IPC: C07K14/71 , A61K38/18 , C07K1/113 , C07K1/16 , C07K1/18 , C07K1/22 , C07K1/36 , C07K16/22 , C07K16/28 , C12N5/00 , C12N15/66 , C12P21/02 , C12P21/06 , G01N30/80 , G01N30/02
CPC classification number: C07K14/71 , A61K38/1866 , C07K1/113 , C07K1/16 , C07K1/18 , C07K1/22 , C07K1/36 , C07K16/22 , C07K16/283 , C12N5/0018 , C12N5/0031 , C12N15/66 , C12P21/02 , C12P21/06 , G01N30/80 , C07K2317/622 , C07K2319/30 , C07K2319/33 , C12N2800/10 , G01N2030/027
Abstract: The present disclosure pertains to methods for producing aflibercept from a host cell cultured in a chemically defined medium (CDM) including purification of aflibercept, wherein aflibercept following purification includes aflibercept variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine and a combination thereof.
-
公开(公告)号：US20240010737A1
公开(公告)日：2024-01-11
申请号：US18175809
申请日：2023-02-28
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： John Mattila , Xiaolin Tang , Hanne Bak , Shawn M. Lawrence , Amy S. Johnson , Meghan Casey , Michelle LaFond , Andrew Tustian , Philip Mellors , John Hourihan , John Crowley , Laura Callinan , Shadia Abike Oshodi , Ashley Witmer , Daniel Corbett , James Reilly , Ankit Vartak , Mark Chiboroski , Alessandra Starling , Robert Stairs , Hai-Yuan Goh , Liam Nicholl , Aishling Conlon
CPC classification number: C07K16/2866 , C07K1/36 , C12N7/00 , B01D15/1871 , B01D15/3809 , B01D15/363 , B01D15/362 , B01D15/327 , B01D61/145 , C07K2317/14 , B01D2315/16
Abstract: The present invention pertains to methods for manufacturing high titer antibody products. In particular, the invention pertains, in part, to improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Additionally, the present invention further pertains to chromatographic procedures employed to successfully isolate the antibody product subject of the present disclosure.
-
公开(公告)号：US20230332201A1
公开(公告)日：2023-10-19
申请号：US18115321
申请日：2023-02-28
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： John Mattila , Xiaolin Tang , Hanne Bak , Shawn M. Lawrence , Amy S. Johnson , Meghan Casey , Michelle LaFond , Andrew Tustian , Philip Mellors , John Hourihan , John Crowley , Laura Callinan , Shadia Abike Oshodi , Ashley Witmer , Daniel Corbett , James Reilly , Ankit Vartak , Mark Chiboroski , Alessandra Starling , Robert Stairs , Hai-Yuan Goh , Liam Nicholl , Aishling Conlon
CPC classification number: C12P21/02 , C12N5/00 , C12M41/46 , C12M41/32 , C07K16/2866 , C12N2500/60 , C12N2500/02 , C12N2501/33 , C12N2500/32 , C12N2500/42 , C07K2317/21
Abstract: The present invention pertains to methods for manufacturing high titer antibody products. In particular, the invention pertains, in part, to improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Additionally, the present invention further pertains to chromatographic procedures employed to successfully isolate the antibody product subject of the present disclosure.
-
公开(公告)号：US20230287043A1
公开(公告)日：2023-09-14
申请号：US18115354
申请日：2023-02-28
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： John Mattila , Xiaolin Tang , Hanne Bak , Shawn M. Lawrence , Amy S. Johnson , Meghan Casey , Michelle LaFond , Andrew Tustian , Philip Mellors , John Hourihan , John Crowley , Laura Callinan , Shadia Abike Oshodi , Ashley Witmer , Daniel Corbett , James Reilly , Ankit Vartak , Mark Chiboroski , Alessandra Starling , Robert Stairs , Hai-Yuan Goh , Liam Nicholl , Aishling Conlon
CPC classification number: C07K1/36 , C12N5/0031 , C07K16/468 , C12N2500/33 , C12N2500/46 , C12N2501/33 , C12N2500/10
Abstract: The present invention pertains to methods for manufacturing high titer antibody products. In particular, the invention pertains, in part, to improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Additionally, the present invention further pertains to chromatographic procedures employed to successfully isolate the antibody product subject of the present disclosure.
-
公开(公告)号：US20230272044A1
公开(公告)日：2023-08-31
申请号：US18118558
申请日：2023-03-07
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Andrew Tustian , Ankit Vartak , Thomas Daly , Erica Pyles , Nisha Palackal
IPC: C07K14/71 , C12P21/06 , C07K1/113 , C07K1/16 , C07K1/36 , C12N5/00 , C07K1/18 , C07K1/22 , C12P21/02 , A61K38/18 , C07K16/28 , C12N15/66 , C07K16/22 , G01N30/80
CPC classification number: C07K14/71 , C12P21/06 , C07K1/113 , C07K1/16 , C07K1/36 , C12N5/0018 , C12N5/0031 , C07K1/18 , C07K1/22 , C12P21/02 , A61K38/1866 , C07K16/283 , C12N15/66 , C07K16/22 , G01N30/80 , C07K2319/30 , C12N2800/10 , C07K2317/622 , C07K2319/33 , G01N2030/027
Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins.
